Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2004 2
2005 1
2008 1
2009 1
2011 6
2012 5
2013 5
2014 3
2015 2
2016 2
2017 2
2018 2
2019 2
2020 7
2021 4
2022 2
2023 3
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Impact of sickle cell disease on patients' daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY).
Osunkwo I, Andemariam B, Minniti CP, Inusa BPD, El Rassi F, Francis-Gibson B, Nero A, Trimnell C, Abboud MR, Arlet JB, Colombatti R, de Montalembert M, Jain S, Jastaniah W, Nur E, Pita M, DeBonnett L, Ramscar N, Bailey T, Rajkovic-Hooley O, James J. Osunkwo I, et al. Am J Hematol. 2021 Apr 1;96(4):404-417. doi: 10.1002/ajh.26063. Epub 2021 Feb 25. Am J Hematol. 2021. PMID: 33264445 Free PMC article.
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP; Investigators of the Phase 3 Trial of l-Glutamine in Sickle Cell Disease. Niihara Y, et al. Among authors: osunkwo i. N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971. N Engl J Med. 2018. PMID: 30021096 Free article. Clinical Trial.
A clinician's view of voxelotor.
Osunkwo I, Anderson A, Brown RC, Shah N, Estepp JH. Osunkwo I, et al. Br J Haematol. 2022 Nov;199(4):616-618. doi: 10.1111/bjh.18455. Epub 2022 Sep 16. Br J Haematol. 2022. PMID: 36113859 No abstract available.
Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.
Saraf SL, Hagar R, Idowu M, Osunkwo I, Cruz K, Kuypers FA, Brown RC, Geib J, Ribadeneira M, Schroeder P, Wu E, Forsyth S, Kelly PF, Kalfa TA, Telen MJ. Saraf SL, et al. Among authors: osunkwo i. Blood Adv. 2024 Aug 27;8(16):4459-4475. doi: 10.1182/bloodadvances.2023012467. Blood Adv. 2024. PMID: 38640200 Free PMC article. Clinical Trial.
Optimizing the management of chronic pain in sickle cell disease.
Osunkwo I, O'Connor HF, Saah E. Osunkwo I, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):562-569. doi: 10.1182/hematology.2020000143. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275672 Free PMC article. Review.
49 results